Bone marrow transplantation is considered to be the treatment of choice for various hematological and solid malignancies, as well as for bone marrow failure syndromes and some genetic diseases. Unfortunately, a great number of patients who receive allogeneic BMT suffer from graft-versus-host disease (GVHD) following the procedure. Xerostomia is considered to be one of the most annoying complications of chronic GVHD (cGVHD), and the rapidly growing number of BMT patients with prolonged survival renders GVHD-related xerostomia a major clinical problem. As pilocarpine hydrochloride has been shown to relieve xerostomia in other disease categories, we administered pilocarpine hydrochloride 30 mg/day to six cGVHD patients and measured their whole saliva, parotid and submandibular-sublingual flow rates in both resting and stimulated conditions. Mean values of flow rates of whole saliva in resting conditions at 2 weeks, 2 months and 6 months following administration of pilocarpine hydrochloride 30 mg/day were 0.71 ؎ 0.12 ml/min, 0.59 ؎ 0.07 ml/min and 0.56 ؎ 0.11 ml/min, respectively. In stimulated conditions, mean values were 1.7 ؎ 0.3 ml/min, 1.0 ؎ 0.17 ml/min and 0.94 ؎ 0.21 ml/min, respectively. The mean values of whole saliva flow rates under both conditions represented an increase of 224-284% and 134-247%, respectively (P Ͻ 0.01). The pattern and magnitude of parotid and submandibular-sublingual flow rate increases following pilocarpine hydrochloride administration were similar. Patients were followed for 6 months and demonstrated increased levels of secretion, with some reduction after the initial peak values. The medication was discontinued at 2 months and reinstated after 2 weeks in three patients. This resulted in rapid flow rate reduction followed by another profound increase. Contrary to the sialometrical analysis, the subjective scoring showed no fluctuations during the study period. We discuss these results in the context of the clinical experience of xerostomic patients in whom even a minute increase in secretion may be significant. Our results demonstrate that objective and subjective relief from xerostomia in cGVHD patients can be achieved with the routine oral administration of pilocarpine hydrochloride.
Bone marrow transplantation is currently considered the treatment of choice for various hematological and solid malignancies, as well as some bone marrow failure syndromes and genetic diseases. 1 Unfortunately, 40-70% of patients suffer from acute or chronic graft-versus-host disease (GVHD) following allogeneic BMT, despite the prophylactic regimen used. GVHD is caused by donor graft T-lymphocytes which recognize antigenic disparities between donor and recipient. 2, 3 Tissue damage associated with GVHD is thought to be caused by infiltrative T cellmediated cytotoxicity, with target organs and tissues including oral and gastrointestinal mucosa, skin, liver, pancreas, lacrymal and salivary glands. [4] [5] [6] [7] GVHD is viewed today as a three-step process, consisting of upregulation of HLA and leukocyte adhesion molecules on host target cells, followed by activation of donor immunocompetent T cells by host histocompatibility antigens which then proliferate. Finally, these activated T cells secrete cytokines, recruit additional cells, induce the expression of histocompatibility antigens and focus their attack on recipient targets. 8 GVHD is known to cause damage to both the oral cavity and the salivary glands. 9, 10 Salivary gland involvement in GVHD is indicated by increased xerostomia, accompanied by decreased levels of salivary immunoglobulins and increased incidence of oral infections, [11] [12] [13] a change in saliva composition, and histopathological changes in the labial minor salivary glands. [9] [10] [11] 13 These pathological changes resemble the alterations observed in a Sjögren-like syndrome. 5, 6 The significant involvement of salivary glands in the disease gained further support recently when lymphocyte infiltration into the major salivary gland in murine models of both acute and chronic GVHD (cGVHD) and in patients who clinically suffered from xerostomia, 7, 14, 15 was demonstrated. In animal models, a direct relationship between xerostomia and the level of lymphocyte infiltration was shown. The xerostomia developing in GVHD patients results in subjective suffering and disturbances in chewing, swallowing and speaking, along with increased levels of dental caries and oral candidiasis. 12, 16 The available treatment options, such as salivary substitutes, are largely palli-ative and usually offer only short-term relief. Pilocarpine, a cholinergic agonist, has been long known to stimulate salivary secretion. [16] [17] [18] Some encouraging studies published in recent years have demonstrated the efficacy of oral pilocarpine hydrochloride in partially relieving xerostomia in post-head and neck radiotherapy patients. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Therefore, we investigated the efficacy of pilocarpine hydrochloride on xerostomia in cGVHD patients. The effect was evaluated by both objective parameters, including sialometric studies, measuring whole saliva and parotid and submandibular flow rates at both resting and stimulated conditions, and by subjective parameters.
Materials and methods

Patients
Six consenting patients (four males, two females) with cGVHD, diagnosed according to the Seattle criteria, 3, 4 median age 22 years (range, 18-39), were entered into this study (Table 1) . Four patients had limited, moderate cGVHD, while two had extensive, severe cGVHD. Organ involvement included skin, eyes, mucosa and salivary glands in all six patients, and liver in one. All patients had been conditioned with total body irradiation (TBI) 1200 cGy (200 cGy × 2 × 3 days) and cyclophosphamide 60 mg/kg × 2 days, and underwent non-T cell-depleted peripheral blood stem cell transplantation (PBSCT). Age, sex and basic disease status at transplantation are shown in Table 1 . Mean time from PBSCT to onset of cGVHD was 5.7 Ϯ 1.3 months.
Study design
The first three patients with cGVHD (patients 1-3; Table 1 ) received pilocarpine hydrochloride (Salagen, MGI Pharma, Minneapolis, MN, USA) 30 mg/day for 6 months. Sialometrical studies, including measurements of whole saliva, parotid and submandibular flow rates in both resting and stimulated conditions, as well as subjective parameters, were performed pre-study, every week for the first month, every 2 weeks for the entire study period (6 months) and According to Seattle criteria. 3, 4 cGVHD = chronic graft-versus-host disease; M = male; F = female; ALL = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; CML = chronic myelogenous leukemia; NHL = non-Hodgkin's lymphoma; CP = chronic phase; CR = complete remission; R = relapse; S = skin; O = ophthalmic; M = mucosa; Sal = salivary glands; L = liver.
for 2 weeks after the medication was stopped. The next three cGVHD patients (patients 4-6; Table 1 ) were examined by the same salivary parameters on the same timetable, but the pilocarpine hydrochloride 30 mg/day was stopped in these patients after 2 months of therapy, reinstated 2 weeks later and continued until the end of the 6-month study period. This schedule was used to assess the efficacy of continuous treatment vs relatively short-term therapy on the salivary glands.
Subjective evaluation of salivary function
Subjective salivary function was measured by patients' rating of the following parameters from 0 to 4: (1) dryness of mouth; (2) necessity to drink or rinse mouth often; (3) difficulties in mastication, swallowing or speaking; (4) taste aberrations or burning sensation in the mouth. A higher score indicated more oral dryness, a greater necessity to drink, etc.
Sialometry
Major salivary gland flow rates (whole saliva, parotid secretion and submandibular/sublingual secretions) were determined under both resting and stimulated conditions, as previously described. 12, 16 Specimens were obtained in the morning. No oral stimulus was permitted for 90 min prior to collection. Carlson Crittenden cups were used bilaterally to obtain parotid saliva, and the submandibular/ sublingual (SM/SL) saliva was collected simultaneously by standardized gentle suction. Following the collection of unstimulated (resting) saliva, the stimulated saliva was obtained after a 2% citric acid solution was applied to the tongue dorsum bilaterally for 5 min at 30-s intervals. Salivary gland flow rates are expressed as volume of saliva secreted (ml) per min.
Statistical evaluation
Mean and standard errors at the baseline and various time points examined were calculated for all the sialometrical results obtained. The results between baseline and the various time points were compared by using t-test for paired differences (0.01 level of significance).
Results
Side-effects
All patients complained of sweating approximately 1-2 h after administration of the medication, also the main complaint in other studies, 21 but there were no other side-effects and no need to stop or reduce the medication.
Subjective evaluation of salivary function
Prior to the start of the study, cGVHD patient rating on four questions relating to oral dryness was 2.3 Ϯ 0.3 (P Ͻ 0.01), indicating a greater degree of oral dryness, significantly higher than the mean score of 0.0 for patients who underwent allogeneic BMT but who did not develop cGVHD. 12 However, after 2 weeks until the end of the 6-month study period, patients receiving pilocarpine hydrochloride 30 mg/day reported normal scoring (0.0) subjectively, unrelated to fluctuations in sialometrical results. Some patients even reported hypersalivation.
Whole saliva sialometrical analysis
The mean flow rate values of whole saliva under resting conditions at 2 weeks, 2 months and 6 months following administration of pilocarpine hydrochloride 30 mg/day were increased by 224-284% (P Ͻ 0.01) when compared to mean pre-study values (Table 2, Figure 1) . The mean flow rates values of whole saliva under stimulated conditions at the same time points and following administration of the same dosage of pilocarpine hydrochloride were increased by 134-242% (P Ͻ 0.01) when compared to mean pre-study values (Table 2, Figure 1 ).
Parotid gland sialometrical analysis
Mean values of parotid flow rates under resting conditions at 2 weeks, 2 months and 6 months following administration of pilocarpine hydrochloride 30 mg/day were increased by 182-230% (P Ͻ 0.01) when compared to mean pre-study values (Table 2, Figure 1 ). The mean values of flow rates of the parotid gland under stimulated conditions at the same time points and following administration of the same dosage of pilocarpine hydrochloride were increased by 192-268% (P Ͻ 0.01) when compared to mean pre-study values (Table 2, Figure 1 ).
Submandibular/sublingual gland (SM/SL) sialometrical analysis
Mean flow rate values of the SM/SL gland under resting conditions at 2 weeks, 2 months and 6 months following administration of pilocarpine hydrochloride 30 mg/day were increased by 200-300% (P Ͻ 0.01) when compared to mean pre-study values (Table 2, Figure 1 ). The mean Table 2 Sialometric analysis values of flow rates of the SM/SL gland under stimulated conditions at the same time points and following administration of the same dose of pilocarpine hydrochloride were increased by 206-248% (P Ͻ 0.01) when compared to mean pre-study values (Table 2, Figure 1 ).
Whole saliva flow rates following discontinuance and reinstitution of pilocarpine hydrochloride
At 2 months, drug administration was discontinued in three patients (patients 4-6; Table 1 ). Two weeks later, at 2.5 months from the start of the study, whole saliva flow rate values had dropped from 0.58 Ϯ 0.15 ml/min to 0.26 Ϯ 0.05 ml/min at resting conditions and from 1.00 Ϯ 0.17 ml/min to 0.63 Ϯ 0.04 ml/min under stimulated conditions (P Ͻ 0.01) (Figure 1 ). At this point, pilocarpine hydrochloride 30 mg/day was reinstituted and continued for the rest of the study period. After another 2 weeks, at 3 months from the start of the study, flow rates were profoundly increased to levels similar to that found immediately after initial drug administration. However, only 2 weeks later, at 3.5 months from the start of the study, flow rates dropped back to values similar to those found before the medication was interrupted and to that found in patients who received the medication continuously, to 0.55 Ϯ 0.07 ml/min and 1.08 Ϯ 0.18 ml/min, respectively (P Ͻ 0.01) (Figure 1 ). From this point on, there were no significant differences between the mean flow rate values of these three patients, in comparison to the patients who received the medication continuously. This pattern of response for whole saliva was also true for parotid and SM/SL flow rates under both resting and stimulated conditions ( Figure 1 ). No statistical differences were observed in the subjective score or in the various sialometrical parameters following pilocarpine hydrochloride therapy between the two patients with extensive, severe cGVHD (patients 2, 3; Table 1 ) and the four patients with limited, moderate cGVHD (patients 1, 4-6; Table 1 ) (data not shown). Whole saliva flow rates of cGVHD patients on pilocarpine hydrochloride 30 mg/day for 3.5 months at resting (a) and stimulated (b) conditions. At 2 months, the drug was discontinued (---b---) in three of the six patients and reinstituted 2 weeks later, while the other three patients (-ć-) received the medication continuously.
Discussion
We evaluated the effects of oral pilocarpine on xerostomia in cGVHD patients and were able to demonstrate significant improvement in both subjective and objective parameters of salivation. The effect of pilocarpine hydrochloride on salivary functions in our cGVHD patients was rapid, profound and highly significant, and was observed also in patients with extensive, severe cGVHD. This extensive response may be attributed to the high dose of pilocarpine hydrochloride administered, the maximal dose recommended in both animal and human studies. [17] [18] [19] [20] [21] 25, 26 Within 2 weeks of drug administration, the subjective xerostomic score was altered to normal. Similar levels of salivary increase have been previously reported in other groups of patients following head and neck irradiation and in patients suffering from Sjögren's syndrome. [19] [20] [21] 23, 24 It is noteworthy that we found a similar response to the medication under both resting and stimulated conditions, and for both major salivary glands and whole saliva. Similarly, under resting and stimulated conditions, whole saliva, parotid and SM/SL flow rates increased by 284%, 230% and 200%, and by 242%, 268% and 248%, respectively (P Ͻ 0.01). The similarity between the effect of the medication on major salivary glands and on whole saliva may suggest a direct effect of pilocarpine on the salivary glands under various physiological conditions, as it is well known that whole saliva contains secretions from sources other than the salivary glands, such as the gingival sulcus and the oral mucosa. 16, 22, 25 Interestingly, while the subjective effect of the medication was reported as complete throughout its administration, objective results demonstrated a moderate partial reduction with continuous fluctuations as compared to the initial peak levels (Figure 1) . A similar phenomenon was reported by Fox 24 for pilocarpine-treated patients who had received head and neck irradiation. Unfortunately, no other studies evaluating the differential response to pilocarpine in GVHD patients are available although subjective examination of whole saliva following pilocarpine hydrochloride administration was reported in two studies. 26, 27 Thus, the subjective salivary improvement might result from the fact that, over time, small increases in the amount of saliva may be sufficient for clinical improvement (especially for patients whose baseline salivary conditions were low). 24 Furthermore, subjective relief from xerostomia is greatly dependent on the composition of the secreted saliva and not just its amount. Any increase in salivation, no matter how small, which is accompanied by increases in the production of beneficial constituents, may be of benefit to xerostomia patients. Constituents such as mucous provide protection in the mouth against chemical, infectious and mechanical insults, supply lubrication and prevent desiccation of soft tissues. 25 Indeed, pilocarpine has been reported to stimulate salivary constituents, including mucous, proteins, amylase, glycoproteins and electrolytes. 28, 29 At 2 months, administration of pilocarpine hydrochloride was discontinued in three patients, resulting in a flow rate reduction to nearly baseline. Two weeks later, when the medication was reinstituted, a rapid, profound increase was seen, similar to that noted initially, followed by a partial decrease later. Clinically, this observation indicates the need for continuous administration of pilocarpine hydrochloride to cGVHD patients to achieve on-going relief from xerostomia.
In conclusion, the results of this study demonstrated the capacity of pilocarpine hydrochloride 30 mg/day to completely relieve xerostomia in cGVHD patients. Drug administration was accompanied by only mild, transient, and acceptable side-effects. The effect of this medication on the various major salivary glands under varying physiological conditions has been shown and the need for continuous long-term administration in cGVHD patients is emphasized.
